Blood transfusion in marrow graft recipients
- PMID: 1511059
- DOI: 10.1007/BF01698131
Blood transfusion in marrow graft recipients
Abstract
Of 182 consecutive patients undergoing allogeneic bone marrow transplantation (BMT), the relative numbers of those who received red blood cells (RBC), platelets (PLT), and granulocytes were 82%, 96%, and 26%, respectively. The transfused patients received an average of 1.26 (SD +/- 2.0) RBC units, 9.41 (SD +/- 13.2) PLT transfusions, and 0.33 (SD +/- 1.1) granulocyte concentrates per week per 50 kg body wt. in the period starting on the day of bone marrow transplantation (BMT) up to 60 days post BMT. The total number of units per transfused patient was 7.7 (range 1-63) RBC, 55.2 (range 2-394) PLT and 6.2 (range 1-36) granulocytes in the same period. Patients with grades II-IV acute graft-versus-host disease (GVHD) needed more RBC and PLT (p less than 0.001) than patients with grades 0-I acute GVHD. Patients with late engraftment required more granulocyte and PLT transfusion than those with early engraftment (p less than 0.05). Patients with high-risk malignancy had greater need for RBC and PLT than "low-risk patients" (p less than 0.02 and p less than 0.01), respectively). Patients with major ABO-incompatible donors showed a greater need for RBC than patients with minor ABO incompatibility (p = 0.02) or ABO identical donors (p = 0.01). Patients with relatively poor estimated survival required the most RBC and PLT.
Similar articles
-
The impact of donor type and ABO incompatibility on transfusion requirements after nonmyeloablative haematopoietic cell transplantation.Br J Haematol. 2010 Apr;149(1):101-10. doi: 10.1111/j.1365-2141.2009.08073.x. Epub 2010 Jan 11. Br J Haematol. 2010. PMID: 20067562 Free PMC article.
-
Hematological support in patients undergoing allogenetic bone marrow transplantation.Recent Results Cancer Res. 1988;108:44-52. doi: 10.1007/978-3-642-82932-1_7. Recent Results Cancer Res. 1988. PMID: 3051211 Review.
-
ABO blood group barrier in allogeneic bone marrow transplantation revisited.Biol Blood Marrow Transplant. 2005 Dec;11(12):1006-13. doi: 10.1016/j.bbmt.2005.07.015. Biol Blood Marrow Transplant. 2005. PMID: 16338623
-
ABO mismatch may affect engraftment in multiple myeloma patients receiving nonmyeloablative conditioning.Transfusion. 2002 Feb;42(2):205-9. doi: 10.1046/j.1537-2995.2002.00027.x. Transfusion. 2002. PMID: 11896336
-
Safety and impact of donor-type red blood cell transfusion before allogeneic peripheral blood progenitor cell transplantation with major ABO mismatch.Transfusion. 2005 Oct;45(10):1676-83. doi: 10.1111/j.1537-2995.2005.00578.x. Transfusion. 2005. PMID: 16181220 Review.
Cited by
-
Recommendations on RBC Transfusion Support in Children With Hematologic and Oncologic Diagnoses From the Pediatric Critical Care Transfusion and Anemia Expertise Initiative.Pediatr Crit Care Med. 2018 Sep;19(9S Suppl 1):S149-S156. doi: 10.1097/PCC.0000000000001610. Pediatr Crit Care Med. 2018. PMID: 30161070 Free PMC article.
-
Platelet and red blood cell utilization and transfusion independence in umbilical cord blood and allogeneic peripheral blood hematopoietic cell transplants.Biol Blood Marrow Transplant. 2011 May;17(5):710-6. doi: 10.1016/j.bbmt.2010.08.017. Epub 2010 Oct 14. Biol Blood Marrow Transplant. 2011. PMID: 20813199 Free PMC article.
-
Recombinant erythropoietin in clinical practice.Postgrad Med J. 2003 Jul;79(933):367-76. doi: 10.1136/pmj.79.933.367. Postgrad Med J. 2003. PMID: 12897214 Free PMC article. Review.
-
Significance of donor-derived isoagglutinins in ABO-Incompatible hematopoietic stem cell transplantation.J Clin Lab Anal. 2008;22(6):383-90. doi: 10.1002/jcla.20269. J Clin Lab Anal. 2008. PMID: 19021268 Free PMC article.
-
Clinical use of rHuEPO in bone marrow transplantation.Med Oncol. 1999 Apr;16(1):2-7. doi: 10.1007/BF02787351. Med Oncol. 1999. PMID: 10382935 Review.
References
MeSH terms
Substances
LinkOut - more resources
Medical